Juntendo Medical Journal, 2026 Perspectives Juntendo Medical Journal 2026 Surgical Challenge of Sublobar Resection for Early-stage Non-small Cell Lung Cancer: Current Status and Future Perspectives Aritoshi HATTORI, Takeshi MATSUNAGA, Mariko FUKUI, Kazuya TAKAMOCHI, Kenji SUZUKI Department of General Thoracic Surgery, Juntendo University School of Medicine, Tokyo, Japan TEL: +81-3-3813-3111 FAX: +81-3-5800-0281 E-mail: ahattori@juntendo.ac.jp 366th Triannual Meeting of the Juntendo Medical Society “Frontier of lung cancer treatment”〔Held on Sep. 11, 2025〕 〔Received Nov. 29, 2025〕 〔Accepted Dec. 4, 2025〕 J-STAGE Advance published date: Feb. 10, 2026 Copyright © 2026 The Juntendo Medical Society. This is an open access article distributed under the terms of Creative Commons Attribution License (CC BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original source is properly credited. doi: 10.14789/ejmj.JMJ25-0062-P 1 Hattori A, et al: Surgical challenge of sublobar resection for early-stage lung cancer recognized on TSCT scan, has also been correlated with less-invasive pathological findings and favorable prognoses4-9). Subsequently, the Lung Cancer Surgical Study Group of the Japan Clinical Oncology Group (JCOG) conducted a cohort study of early periph­ eral lung cancer. They investigated the validity of the TSCT criteria to diagnose non-invasive lung adenocarcinoma for the preoperative identification of pathological non-invasive cancer (JCOG0201)5). Following this observational study, three impor­ tant clinical trials were initiated by the JCOG (JCOG0802/WJOG4607L10), JCOG0804/WJOG4507L11), and JCOG121112)) to evaluate the efficacy of sublobar resection for early-stage lung cancer based on tumor malignancy (Figure 1). The primary result of these studies have already been published and have greatly influenced daily practice. In the mean­ time, based on the results of clinical trials conducted by JCOG Lung Cancer Surgical Study Group, new randomized trials are ongoing to evaluate whether it is possible to apply segmentectomy as an expanded indication for larger tumors greater than 2 cm in size13). In the future, these trials will clarify the significance of sublobar resection and uncover new insights to improve patient survival in lung cancer surgery. In this perspective article, we report the current status and optimal surgical strategy for early-stage lung cancer based on the results of randomized controlled trials by JCOG. Furthermore, as a future perspective, we discuss the possibility of expanding the indications for segmentectomy. Figure 1 2 Indication of sublobar resection for GGO-dominant early-stage lung cancer Following the result of JCOG02015), we started a trial of sublobar resection for peripheral earlystage lung cancer diagnosed by TSCT findings in 2008 (JCOG0804/WJOG4507L). This trial evaluated the efficacy of wide wedge resection for peripheral lung adenocarcinoma radiologically diagnosed as non-invasive, defined as a consolidation-to-tumor ratio (CTR) ≤ 0.2511). This target enrollment of 333 patients was completed in 2011. The primary endp­ oint, 5-year relapse-free survival (RFS), was assessed in 314 patients who underwent sublobar resection. Operative modes were 258 wide wedge resections and 56 segmentectomies. The median pathological surgical margin was 15 mm (range, 0-55). The 5year RFS was 99.7% (90% confidence interval (CI), 98.3-99.9), which met the primary end point, without any local relapse (Figure 2). Grade 3 or higher post­ operative complications, based on the Common Term­ inology Criteria for Adverse Events (CTCAE) v3.0, were observed in 17 patients (5.4%); no grade 4 or 5 events occurred. Furthermore, the 10-year RFS for the 314 patients who underwent sublobar resec­ tion was 98.6% (95% CI: 96.2-99.5), though one local recurrence was observed at the resection margin. This trial concluded that peripheral GGO-dominant lung cancer can be cured by sublobar resection, with wedge resection considered the first choice. Furthermore, based on several retrospective studies and the excellent long-term outcomes of patients with tumors ≤ 3 cm and CTR ≤ 0.5 in the Surgical strategy map in the JOCG Lung Cancer Surgical Study Group Juntendo Medical Journal, 2026 Figure 2 The primary results of JCOG0804/WJOG4507L and JCOG1211 trials JCOG0201 supplemental analysis14), JCOG1211 was designed to assess the efficacy and technical feasi­ bility of segmentectomy in clinical T1abN0 GGOpredominant non-small cell lung cancer (NSCLC) (CTR ≤ 0.5) with tumor diameters up to 3 cm12). The primary endpoint was the 5-year RFS. Segm­ entectomy with hilar, interlobar, and intrapulmo­ nary lymph node dissection was performed, and resection margins exceeding the maximum tumor diameter or at least 2 cm were mandatory. A total of 396 patients were registered, of whom 357 under­ went segmentectomy. At a median follow-up of 5.4 years, the 5-year RFS was 98.0% (95% CI: 95.999.1) (Figure 2). The median pathological surgical margin was 25 mm (range, 17-32). Local relapse occurred only in one patient (0.3%; 95% CI: 0.0-1.4) among the 396 enrolled. Grade 3 or 4 early postop­ erative complications occurred in seven patients (2%), but no grade 5 treatment-related deaths occu­ rred. Based on these results, segmentectomy should be considered part of the standard treatment for patients with predominantly GGO-type NSCLC ≤ 3 cm in diameter, including those with GGO compo­ nents exceeding 2 cm. Together, these two trials demonstrate that GGO-dominant lung cancer is an optimal candidate for sublobar resection and that the optimal choice between wedge resection and segmentectomy should be determined by achiev­ able surgical margin. Indication for segmentectomy in radiologically invasive lung cancer To evaluate the efficacy of segmentectomy or subl­ obar resection for peripherally located, small-sized NSCLC with a radiologically invasive appearance, two randomized phase III trials were conducted: one in Japan (JCOG0802/WJOG4607L)10) and one in North America (CALGB140503)15). In the JCOG and WJOG joint trial, the 5-year overall survival (OS) was 94.3% (95% CI: 92.1−96.0) after segmen­ tectomy and 91.1% (95% CI: 88.4−93.2) after lobec­ tomy. Both superiority and non-inferiority in OS were confirmed using a stratified Cox regression model (HR: 0.663; 95% CI: 0.474-0.927; one-sided p < 0·0001 for non-inferiority; p = 0·0082 for superi­ ority) (Figure 3). At the 1-year follow-up, the diff­ erence in the reduction of median forced expira­ tory volume in 1 second between the groups was 3.5% (p < 0·0001), which did not reach the prede­ fined threshold of 10% for clinical significance. The 5-year RFS was 88.0% (95% CI: 85.0−90.4) after segmentectomy and 87.9% (95% CI: 84.8−90.3) after lobectomy (HR, 0.998; 95% CI: 0.753−1.323; p = 0.9889) (Figure 3). Local relapse occurred in 10.5% of patients after segmentectomy and in 5.4% after lobectomy (p = 0.0018). Among patients who died, 52 of 83 (63%) after lobectomy and 27 of 58 (47%) after segmentectomy died from other diseases. No 30-day or 90-day mortality was observed. Further­ more, a phase III trial conducted in the USA demon­ strated that sublobar resection was not inferior to lobectomy with respect to disease-free survival for peripheral stage IA NSCLC. Taken together, JCOG0802/WJOG4607L and CALGB140503 provide strong evidence for segmentectomy in clinical stage IA, peripherally located, small-sized NSCLC. 3 Hattori A, et al: Surgical challenge of sublobar resection for early-stage lung cancer Figure 3 The primary results of JCOG0802/WJOG4607L and JCOG1211 trial Prevention of the locoregional recurrence for the optimal indication of segmentectomy In JCOG0802/WJOG4607L, the survival benefit of segmentectomy is thought to be related to the preservation of postoperative pulmonary function, which may reduce deaths from other diseases or secondary cancers. Understanding the reason behind this survival advantage is therefore clinically impor­ tant. One important reason is the higher rate of death from other diseases after lobectomy compared with segmentectomy. Furthermore, patients in the segmentectomy group were more frequently able to receive treatment for recurrent or second lung cancers, including a higher rate of repeat surgical resection. This observation implies that segmentec­ tomy preserves physiological reserves, allowing for more intensive treatment of future life-threatening diseases, which improves long-term OS compared with lobectomy. Although segmentectomy demonstrated supe­ rior OS, the incidence of local relapse was higher after segmentectomy than that after lobectomy. In daily practice, radiologically determined pure-solid NSCLCs are known to exhibit more malignant behavior and have a worse prognosis than partsolid NSCLCs with a GGO component. In JCOG0802/ WJOG4607L, however, the 5-year OS was signifi­ cantly higher after segmentectomy than lobectomy in patients with radiologically pure-solid NSCLC (86.1% [95% CI: 81.4-89.7] vs. 92.4% [95% CI: 88.695.0]; HR: 0.64, 95% CI: 0.41-0.97; log-rank test p = 0.033), whereas the 5-year RFS was similar between 4 the groups (81.7% [95% CI: 76.5-85.8] vs. 82.0% [95% CI: 76.9-86.0]; HR 1·01 [95% CI: 0.72-1.42]; p = 0.94)10) (Figure 4). Since the exact mechanisms unde­ rlying this OS advantage remain unclear, a post-hoc supplemental analysis of JCO0802/WJOG4607L was performed to compare survival, cause of death, and recurrence patterns in patients with clinical stage IA, peripherally located, radiologically pure-solid NSCLC16). The results indicated that death from other diseases was twice as common after lobec­ tomy as that after segmentectomy (12.0% vs. 5.7%), whereas locoregional recurrence was twice as common after segmentectomy (16.1% vs. 7.7%, p = 0.0021). In particular, lymph node recurrence was three-fold higher after segmentectomy, and cut-end recurrence occurred exclusively in the segmentec­ tomy group. In an additional supplemental analysis of 529 segmentectomy cases, multivariate analysis revealed two independent predictors of locore­ gional recurrence: a surgical margin smaller than the tumor size (p = 0.0063) and a radiological puresolid tumor (p = 0.0008)17). Importantly, survival outcomes of segmentectomy also differed greatly according to patient physiolog­ ical function, including age and sex, in this post-hoc analysis. In subgroup analyses, better 5-year OS after segmentectomy than lobectomy was observed in the patients aged 70 years or older (77.1% [95% CI: 68.2-83.8] vs. 85.6% [95% CI: 77.5-90.9]; p = 0.013) and in male patients (80.5% [95% CI: 73.785.7] vs. 92.1% [95% CI: 87.0-95.2]; p = 0·0085). In contrast, better 5-year RFS after lobectomy was Juntendo Medical Journal, 2026 Figure 4 The results of JCOG0802/WJOG4607L supplemental analysis focusing on the radiological pure-solid NSCLC Figure 5 The subgroup analysis of JCOG0802/WJOG4607L supplemental analysis based on the patient age or gender among the patients with radiological pure-solid NSCLC observed in patients younger than 70 years (87.4% [95% CI: 812-91.7] vs. 84.4% [95% CI: 77.9-89.1]; p = 0.049) and in female patients (94.2% [95% CI; 87.6-97.4] . 82.2% [95% CI: 73.2-88.4]; p = 0.047) (Figure 5). These results highlight the need for further research to refine the clinical indications for segmentectomy in radiologically pure-solid NSCLC and to determine the optimal balance between reduced invasiveness and effective cancer control by definitive resection16). Future perspectives on sublobar resection as a treatment for larger tumors (> 2-3 cm) and nodepositive lung cancer For T1cN0 NSCLC, lobectomy is the standard surgical mode. However, comparing segmentectomy 5 Hattori A, et al: Surgical challenge of sublobar resection for early-stage lung cancer with lobectomy in predominantly solid NSCLC (CTR > 0.5) with a tumor diameter of > 2 cm is nece­ ssary for expanding the indications for segmentec­ tomy in the future. There are indications that pred­ ominantly solid tumors possess stronger malignancy characteristics. In particular, pure-solid tumors (CTR = 1.0 without any GGO) on TSCT are reported to have a worse prognosis than part-solid tumors (tumors with GGO)18-29). A supplemental analysis of JCOG0201 showed that pure-solid tumors had a higher frequency of pathological nodal involvement and lower 5-year OS than the part-solid tumors, with this trend becoming more pronounced as clin­ ical stage progresses (5-year overall survival in the GGO group: T1b 93.7% and T1c 91.7%; while in the solid group: T1b 85.9% and T1c 73.7%)30). When pure-solid tumors were included, segmentectomy was inferior to lobectomy for the OS in lung cancers with > 2-cm and ≤ 3-cm tumor diameter according to several large-scale database and retrospective institutional studies in both the USA and Japan31-34). In contrast, a retrospective study reported that when pure-solid tumors on TSCT were excluded, segmentectomy showed similar prognosis compared to lobectomy even in predominantly solid NSCLC with tumor diameter > 2 cm and ≤ 3 cm (5-year OS: 95.5% vs. 90.2%, p = 0.697)35). Based on these results, we expected that segmentectomy would provide good prognosis for patients with predominantly solid NSCLC with GGO on TSCT and tumors > 2 cm and ≤ 3 cm in diameter. Consequently, we excluded pure-solid tumors from this trial because separately analyzing the treatment development for pure-solid tumors of > 2 cm would be more beneficial due to their high-grade malignancy. To date, in the JCOG Lung Cancer Surgical Study Group, a new randomized phase 3 trial is ongoing to confirm the efficacy of segmentectomy for pred­ ominantly solid lung cancer showing GGO in JCOG (JCOG2217; STRONG trial)13) as the next clinical trial following JCOG0802/WJOG4607L (Figure 6). Furthermore, another challenging discussion is arising in the general thoracic surgical community to consider the role of segmentectomy for node-pos­ itive lung cancer. In the JCOG0802/WJOG4607L supplemental analysis, the 5 year-OS of segmen­ tectomy for NSCLC with occult nodal metastasis was superior to that of lobectomy in patients with node-positive lung cancer among a limited number of cases (n = 65, 5 year-OS; 94.4% vs. 78.7%, HR: 0.448, 5%CI: 0.130-1.544, p = 0.1919). Retrospectively, several nationwide or institutional studies have been conducted to evaluate the efficacy of segmentec­ tomy for resectable NSCLC with unsuspected nodal disease. In the National Cancer Database study in the USA, segmentectomy showed equivalent 5 yearOS compared with lobectomy for both the N1 and N2 groups, and a multivariable model revealed that the use of adjuvant chemotherapy significantly improves survival in patients with lymph node metastasis (N1/N2) independent of the type of anatomic lung resection36). Several other studies have Figure 6 The schema of new randomized controlled trial in JCOG Lung Cancer Surgical Study Group (JCOG2217) 6 Juntendo Medical Journal, 2026 demonstrated similar surgical outcomes for this population, suggesting segmentectomy had a favor­ able role and that complete lobectomy is unneces­ sary for occult node positive cases37-41). Clearly, conversion to lobectomy is the mainstay for nodepositive lung cancer when considering definitive locoregional management. However, segmentec­ tomy may potentially improve survival even for this population. Notably, the JCOG0802/WJOG trial indicated a potential benefit of segmentectomy due to the effects of extensive treatment for subsequent life-threatening diseases including lung cancer recur­ rence or secondary disease10). Further discussion is warranted to discuss the expanding indication of segmentectomy in the future. Conclusions In this perspective article, we presented the latest clinical evidence and the operative strategies for small-sized lung cancers. In early-stage lung cancer, the presence of a GGO strongly indicates oncolog­ ical aggressiveness and prognosis. According to these trials, GGO-dominant early-stage lung cancers may be considered optimal candidates for sublobar resection. For radiological invasive NSCLC, segmen­ tectomy is a new standard option for surgical care, while further research is necessary to confirm the clinically relevant indications of segmentectomy for pure-solid NSCLC. To confirm the efficacy of segm­ entectomy for larger tumors, a new randomized phase 3 trial is ongoing for patients with predomi­ nantly solid lung tumors with GGO that is > 2 cm in size. In the future, we hope to expand the indica­ tion of segmentectomy effectively considering the surgical balance between low invasiveness and locoregional cancer control. Acknowledgments We also thank Editage (www.editage.com) for English language editing. Funding This research was supported in part by KAKENHI (Grants-in-Aid for Scientific Research, grant number 21K16522), the Practical Research for Innovative Cancer Control Fund of the Japan Agency for Medical Research and Development (grant numbers 24ck0106973h0001 and 24ck0106974h0001), and the Smoking Research Foundation. Author contributions AH conceptualized the manuscript, performed data curation, formal analysis, investigation, and writing of the original draft. KS, KT, TM, MF contributed to conceptualization of the manuscript and supervised, reviewed, and edited the original draft. Conflicts of interest statement The authors declare that there are no conflicts of interest. References 1) Cahan WG: Radical lobectomy. J Thorac Cardiovasc Surg, 1960; 39: 555-572. 2) Ginsberg RJ, Rubinstein LV: Randomized trial of lobec­ tomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg, 1995; 60: 615-622; discussion 22-3. 3) Aberle DR, Adams AM, Berg CD, et al: Reduced lungcancer mortality with low-dose computed tomographic screening. NEJM, 2011; 365: 395-409. 4) Suzuki K, Asamura H, Kusumoto M, Kondo H, Tsuchiya R: "Early" peripheral lung cancer: prognostic signifi­ cance of ground glass opacity on thin-section computed tomographic scan. Ann Thorac Surg, 2002; 74: 16351639. 5) Suzuki K, Koike T, Asakawa T, et al: A prospective radiological study of thin-section computed tomography to predict pathological noninvasiveness in peripheral clinical IA lung cancer (Japan Clinical Oncology Group 0201). J Thorac Oncol, 2011; 6: 751-756. 6) Suzuki K, Kusumoto M, Watanabe S, Tsuchiya R, Asamura H: Radiologic classification of small adenocar­ cinoma of the lung: radiologic-pathologic correlation and its prognostic impact. Ann Thorac Surg, 2006; 81: 413419. 7) Maeyashiki T, Suzuki K, Hattori A, Matsunaga T, Takamochi K, Oh S: The size of consolidation on thinsection computed tomography is a better predictor of survival than the maximum tumour dimension in rese­ ctable lung cancer. Eur J Cardiothorac Surg, 2012; 43: 915-918. 8) Matsunaga T, Suzuki K, Hattori A, et al: Lung cancer with scattered consolidation: detection of new indepen­ dent radiological category of peripheral lung cancer on thin-section computed tomography. Interdiscip Cardio­ vasc Thorac Surg, 2012; 16: 445-449. 9) Hattori A, Suzuki K, Matsunaga T, et al: Is limited resection appropriate for radiologically "solid" tumors in small lung cancers? Ann Thorac Surg, 2012; 94: 212215. 10) Saji H, Okada M, Tsuboi M, et al: Segmentectomy versus lobectomy in small-sized peripheral non-smallcell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferi­ ority trial. Lancet, 2022; 399: 1607-1617. 11) Suzuki K, Watanabe SI, Wakabayashi M, et al: A single-arm study of sublobar resection for ground- 7 Hattori A, et al: Surgical challenge of sublobar resection for early-stage lung cancer glass opacity dominant peripheral lung cancer. J Thorac Cardiovasc Surg, 2022; 163: 289-301 e2. 12) Aokage K, Suzuki K, Saji H, et al: Segmentectomy for ground-glass-dominant lung cancer with a tumour diameter of 3 cm or less including ground-glass opacity (JCOG1211): a multicentre, single-arm, confirmatory, phase 3 trial. Lancet Respir Med, 2023. 13) Mitome N, Hattori A, Suzuki K, et al: A multi-institu­ tional randomized phase III trial of lobectomy versus segmentectomy for radiologically solid-predominant non-small cell lung cancer with a ground-glass opacity and tumor diameter > 2 cm and 2 cm in maximum tumour size. Interdiscip Cardiovasc Thorac Surg, 2022; 35. 36) Razi SS, Nguyen D, Villamizar N: Lobectomy does not confer survival advantage over segmentectomy for non-small cell lung cancer with unsuspected nodal disease. J Thorac Cardiovasc Surg, 2020; 159: 2469-2483 e4. 37) Mynard N, Nasar A, Rahouma M, et al: Extent of Resec­ tion Influences Survival in Early-Stage Lung Cancer With Occult Nodal Disease. Ann Thorac Surg, 2022; 114: 959-967. 38) Liou DZ, Chan M, Bhandari P, et al: Lobar versus subl­ obar resection in clinical stage IA primary lung cancer with occult N2 disease. European journal of cardio-tho­ racic surgery : Eur J Cardiothorac Surg, 2022; 62. 39) Luo X, Hayanga JWA, Mehaffey JH, et al: Clinical stage IA non-small cell lung cancer with occult pathologic N1 and N2 disease after segmentectomy: does a comple­ tion lobectomy justify? European journal of cardio-tho­ racic surgery : Eur J Cardiothorac Surg, 2024; 66. 40) Nobel TB, Tan KS, Adusumilli PS, et al: Outcomes of Patients Undergoing Segmentectomy for Occult Node- Juntendo Medical Journal, 2026 Positive Clinical Stage IA Lung Cancer. Ann Thorac Surg, 2024; 118: 655-663. 41) Ryuko T, Okazaki M, Toyooka S: Segmentectomy vs Lobectomy in NSCLC With Unsuspected N1/N2: Inter­ preting Real-World Outcomes After Adjustment. Ann Thorac Surg, 2025. 9